Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

ARS Pharmaceuticals, Inc. - Common Stock (NQ:SPRY)

17.45 -0.75 (-4.12%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,160,616
Open 18.43
Bid (Size) 17.10 (1)
Ask (Size) 17.50 (1)
Prev. Close 18.20
Today's Range 16.19 - 18.50
52wk Range 8.350 - 18.90
Shares Outstanding 95,568,307
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Jim Cramer Is All Aboard Union Pacific, But Shows No Love For Orphan Drugs
Jim Cramer recommends Union Pacific but is "getting tired of the orphan drug model." Here's what the "Mad Money" host said. 
Via Benzinga
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
+62.9%
+62.9%
1 Month
+20.9%
+20.9%
3 Month
+38.7%
+38.7%
6 Month
+64.3%
+64.3%
1 Year
+99.9%
+99.9%

More News

Read More
ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray)
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Pharmaceuticals's Earnings: A Preview
Via Benzinga
Earnings Scheduled For May 14, 2025
Via Benzinga
ARS Pharmaceuticals’ neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Which stocks are gapping on Thursday?
Via Chartmill
ARS Pharma Retakes Its 50-Day Line In Bullish Post-Earnings Move. Here's Why.
Via Investor's Business Daily
Jabil Posts Better-Than-Expected Earnings, Joins Darden Restaurants, QXO, Five Below And Other Big Stocks Moving Higher On Thursday
Via Benzinga
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Earnings Scheduled For March 20, 2025
Via Benzinga
FDA Approves ARS Pharmaceuticals' Lower Dose Neffy Nasal Spray For Emergency Allergy Treatment
Via Benzinga
ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Conference
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review
Via Investor's Business Daily
Topics Economy
BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.
Via Investor's Business Daily
ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy® (epinephrine nasal spray)
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is ARS Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, ARS Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does ARS Pharmaceuticals, Inc. - Common Stock trade on?
ARS Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ARS Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for ARS Pharmaceuticals, Inc. - Common Stock is SPRY on the Nasdaq Stock Market
What is the current price of ARS Pharmaceuticals, Inc. - Common Stock?
The current price of ARS Pharmaceuticals, Inc. - Common Stock is 17.45
When was ARS Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of ARS Pharmaceuticals, Inc. - Common Stock was at 06/30/25 04:00 PM ET
What is the market capitalization of ARS Pharmaceuticals, Inc. - Common Stock?
The market capitalization of ARS Pharmaceuticals, Inc. - Common Stock is 1.67B
How many shares of ARS Pharmaceuticals, Inc. - Common Stock are outstanding?
ARS Pharmaceuticals, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.